Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.59 |
| ▸ | CTSL | P07711 | 3/20 | 0.59 |
| ▸ | CTSB | P07858 | 3/20 | 0.59 |
| ▸ | CTSS | P25774 | 2/20 | 0.59 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7134280 | 0.85 | CTSB (0.46) | CTSKCTSLCTSBCTSSLMNA | |
| SCHEMBL7137827 | 0.85 | CTSL (0.58) | CTSKCTSLCTSBCTSSPSMB5 | |
| SCHEMBL2735629 | 0.80 | LMNA (0.61) | CTSKCTSLCTSBCTSSPSMB5 | |
| SCHEMBL22582338 | 0.79 | MMP2 (0.48) | CTSBPSMB5CASP3LMNA | |
| SCHEMBL7131875 | 0.78 | CTSS (0.53) | CTSKCTSLCTSBCTSSPSMB5 | |
| SCHEMBL7435315 | 0.77 | CTSL (0.50) | CTSLCTSBPSMB5CASP3 | |
| SCHEMBL7435291 | 0.77 | CTSL (0.50) | CTSLCTSBPSMB5CASP3 | |
| SCHEMBL7048560 | 0.77 | CTSS (0.82) | CTSKCTSLCTSBCTSS | |
| SCHEMBL7139836 | 0.77 | PSMB5 (0.49) | CTSKCTSLCTSBCTSSPSMB5 | |
| SCHEMBL7138668 | 0.77 | CTSS (0.49) | CTSKCTSLCTSBCTSSPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | CTSK 29/4885CTSL 14/4885CTSB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.